Back to top
more

Argenx (ARGX)

(Delayed Data from NSDQ)

$877.72 USD

877.72
351,969

-14.54 (-1.63%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $877.31 -0.41 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Perrigo (PRGO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Zacks Equity Research

Editas (EDIT) Soars 20.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Editas (EDIT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Geron (GERN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on updates on Geron's (GERN) lead pipeline candidate when it reports its fourth-quarter earnings.

Zacks Equity Research

Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) Soars 6.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Halozyme (HALO) Down 9.2% on Weak 2023 Financial Guidance

by Zacks Equity Research

Though Halozyme (HALO) expects a year-over-year increase in revenues and earnings for 2023, the company's guidance fell short of Wall Street expectations.

Zacks Equity Research

argenex SE (ARGX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why

by Zacks Equity Research

Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues on the back of robust demand for its new partnered drugs.

Zacks Equity Research

Why Earnings Season Could Be Great for argenx (ARGX)

by Zacks Equity Research

argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Sundeep Ganoria headshot

4 Biotech Stocks Set to Outpace Q3 Earnings Estimates

by Sundeep Ganoria

Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.